Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil. International Breast Cancer Study Group.
Combined chemotherapy for early breast cancer with cyclophosphamide, methotrexate, and fluorouracil has low associated mortality, but related deaths were seen among women aged 65 years or older in International Breast Cancer Study Group trials.
M
M
Colleoni
K N
KN
Price
M
M
Castiglione-Gertsch
R D
RD
Gelber
A S
AS
Coates
A
A
Goldhirsch
D000328:Adult; D000367:Age Factors; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000009:adverse effects; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects; D006801:Humans; D008727:Methotrexate / Q000009:adverse effects; D008875:Middle Aged; D017698:Postmenopause; D017697:Premenopause
D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate